XIAP and non-Hodgkin lymphoma: Other promising ASOs under clinical investigation are the following: cenersen against TP53 in MDS; the anti-c-myb G4460 for CML treatment in both chronic and accelerated phase; the anti-X-linked inhibitor of apoptosis protein (XIAP) AEG35156 for relapsed or refractory CLL and indolent B cell lymphomas, AML in combination with standard chemotherapy, or refractory/relapsed AML [21,22]; the anti- Hypoxia-inducible factor(HIF)-1α EZN-2968 and the anti- signal transducer and activator of transcription(STAT)3 AZD9150 and IONIS-STAT3Rx for non-Hodgkin lymphoma treatment (Table 1) [4].